MaxLife Technologies Inc. dba Maxlife
Has MaxLife Technologies Inc. dba Maxlife received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued MaxLife Technologies Inc. dba Maxlife a warning letter naming semaglutide and tirzepatide, dated Feb 20, 2026, with the FDA subject line “False & Misleading Claims/Misbranded (Telehealth).”
FDA records in this index name MaxLife Technologies Inc. dba Maxlife on Feb 20, 2026.
- Websites the letters name
- maxlife.com (see how each letter refers to them)
- Type named in FDA records
- Telehealth
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Feb 20, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Feb 20, 2026 | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Feb 20, 2026: … your website offers compounded drug products, including semaglutide and tirzepatide drug products. 1 As described … website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) … is false or misleading in any particular. The compounded semaglutide and tirzepatide products displayed on your … Full letter
Websites named in the letters
Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.
- maxlife.com: FDA’s warning letter of Feb 20, 2026 is addressed to MaxLife Technologies Inc. dba Maxlife. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.